甘李药业加冕“单项冠军” 长秀霖 二十年深耕打通欧盟之路

Core Insights - 甘李药业 has been recognized as a manufacturing single champion enterprise, marking its status as a leading company in the biopharmaceutical sector with its core product, "Insulin Glargine Injection" [1][2] - The recognition reflects 甘李药业's advanced production technology and significant market share in the insulin analogs field, breaking the long-standing foreign monopoly in the domestic insulin market [1][2] Group 1: Company Achievements - 甘李药业 has established a self-controlled production system and a complete product line, including long-acting, rapid-acting, and premixed insulin [2] - The company has successfully passed the European Medicines Agency (EMA) GMP inspection, laying a solid foundation for entering the global regulated market [2] - In the first three quarters of 2025, domestic formulation revenue reached 2.624 billion yuan, a year-on-year increase of 45.6%, indicating a robust recovery in the domestic market [2] Group 2: Innovation and Future Prospects - Under the leadership of CEO Dr. Chen Wei, 甘李药业 is accelerating the development and global registration of innovative drugs, transitioning from "China's first imitation" to "global first creation" [3] - The company is expected to play a more significant role in the global value chain of the pharmaceutical industry, driven by steady growth in the domestic procurement market and accelerated expansion in the international high-end market [3]